- Increased Scrutiny by Federal Trade Commission of Orange Book ...🔍
- FTC Expands Patent Listing Challenges🔍
- US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents ...🔍
- How Orange Book Antitrust Scrutiny is Intensifying🔍
- FTC continues to scrutinize Orange Book patent listings🔍
- The Current Status of FTC's Orange Book Listings Challenge🔍
- FTC Challenges More Than 100 Patents as Improperly Listed in the ...🔍
- The FTC Challenges Companies' Allegedly Improper Orange Book ...🔍
Increased Scrutiny by Federal Trade Commission of Orange Book ...
Increased Scrutiny by Federal Trade Commission of Orange Book ...
Increased Scrutiny by Federal Trade. Commission of Orange Book Listings. By Deepro R. Mukerjee, Lance A. Soderstrom, Brian Sodikoff,. Matthew M ...
Increased Scrutiny by Federal Trade Commission of Orange Book ...
The FTC has primarily targeted device patents that do not mention any drug in their claims, arguing that such patents do not meet the statutory criteria for an ...
FTC Expands Patent Listing Challenges, Targeting More Than 300 ...
Improper Orange Book patent listings can delay cheaper generic alternatives from entering the market, keeping brand name drug prices ...
US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents ...
... more than 100 patents in the Orange Book. In addition, the FTC submitted patent listing dispute letters to FDA seeking removal or correction ...
... more aggressive approach challenging Orange Book listings as an anticompetitive practice. According to the Federal Trade Commission ...
FTC continues to scrutinize Orange Book patent listings - DLA Piper
The Federal Trade Commission (FTC) sent its second set of warning letters to 10 companies disputing the accuracy or relevance of more than ...
The Current Status of FTC's Orange Book Listings Challenge
... FTC announced its intention to challenge more than one hundred Orange Book listings as improper.6 About six months later, on April 30, 2024 ...
FTC Challenges More Than 100 Patents as Improperly Listed in the ...
The Orange Book is a list of drug products approved by the FDA as safe and effective. When a brand pharmaceutical company lists a patent in the ...
The FTC Challenges Companies' Allegedly Improper Orange Book ...
The FTC is stepping up its initiative to challenge what it views as improper patent listings in FDA's Orange Book, applying pressure on branded ...
The FTC's Criticism of “Junk” Orange Book Filings - Ropes & Gray LLP
The FTC's recent Orange Book scrutiny is propelled by a similar ... Federal Trade Commission, FTC Challenges More Than 100 Patents as ...
An Antitrust Economist's Perspective on Recent FTC Scrutiny ...
The Federal Trade Commission (FTC) has taken several actions to challenge patents listed in the Food and Drug Administration's (FDA) Orange Book.
How Orange Book Antitrust Scrutiny Is Intensifying
... more aggressive approach challenging Orange Book listings as an anticompetitive practice. According to the Federal Trade Commission ...
How Orange Book Antitrust Scrutiny is Intensifying | PDF
... FTC, meaning brand manufacturers' Orange Book listings are facing increasing scrutiny from multiple angles. This article discusses the ...
The FTC's Challenge to the Listing of Device Patents in the Orange ...
The FTC issued a policy statement advising it would be putting market participants on notice that it intends to scrutinize improper Orange Book listings.
Primer: FTC Scrutinizes Orange Book Listings - AAF
The FTC sent notice letters – the first tranche in November 2023 and the second in April 2024 – to drug manufacturers challenging more than 400 ...
FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 ...
The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA's official publication of approved ...
Orange Book Scrutiny Will Increase Despite Inhaler Price Caps
Federal Trade Commission (FTC) Chair Lina Khan says capping inhaler prices and not delisting patents from the Orange Book are two separate ...
Federal Trade Commission Warns Against Improper Orange Book ...
... Orange Book that do not meet the statutory listing criteria.” FTC Promises More Scrutiny of Orange Book Listings. The stated goal of the ...
FTC Issues Policy Statement on Brand Pharmaceutical ...
The FTC will scrutinize improper Orange Book patent listings as potential unfair methods of competition in violation of Section 5 of the FTC Act ...
Teva to be investigated by FTC, ramping up scrutiny of Orange Book ...
To read more · Register for limited access · Subscribe to unlock unlimited access · Already have access? Login below · Related Topics.